The company’s consolidated net profit stood at ₹163 crore for the June quarter, up from ₹85 crore a year earlier. Revenue from operations rose 40.1% year-on-year to ₹1,888.2 crore, compared with ₹1,348 crore in the corresponding quarter last year.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased more than four-fold to ₹139.1 crore from ₹34.2 crore a year ago. EBITDA margin expanded to 7.37% from 2.54%, reflecting improved operating leverage.
The company said total insurance premium, excluding GST, grew 41% year-on-year during the quarter, while protection premium from health and term insurance increased 53%.
Core online insurance premium also rose 41%, while core online lending disbursals grew 33% year-on-year, indicating that the credit business continues to maintain strong momentum.
PB Fintech added that growth in core new insurance premium, excluding the savings business, remained robust at 48% year-on-year, marking the 13th consecutive quarter of growth above 34%. The company also maintained customer satisfaction scores above 90% by strengthening onboarding and claims support, which it believes will support long-term profitability.
Its PB Partners agent aggregation platform continued to scale, with more than 500,000 advisors on the platform and active partners rising 55% year-on-year to 1.13 lakh.
Also read: Godrej Agrovet Q1 profit falls 14% as margin pressure offsets revenue growth
The platform is now present across nearly 19,000 pin codes, with Tier-II and Tier-III markets contributing 78% of overall gross written premium during the quarter. Premium sourced through PB Partners increased 46% year-on-year to ₹1,637 crore, while revenue grew 47% to ₹561 crore.
The company’s UAE insurance business also maintained its growth trajectory, with premium rising 31% year-on-year while remaining profitable, supported by a higher contribution from health and life insurance products.
PB Fintech said its new initiatives business recorded 35% year-on-year revenue growth during the quarter, while adjusted EBITDA margin improved to negative 5% from negative 6% a year ago, signalling continued progress towards profitability.
Shares of the company ended 1.92% higher at ₹1,627.70 ahead of the results announcement on Wednesday. The stock has declined about 10% so far in 2026 and nearly 7% over the past 12 months.
Also read: Biocon Q1 Results: Net profit jumps over four-fold as biopharma business drives growth
